ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1055

Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort

Vanissa Savarimuthu1, Alexandra Ladouceur2, Oliver Terry1, Janet Roberts3, Janet Pope4, Thomas Appleton4, Sabrina Hoa5, Aurore Fifi-Mah6, Nancy Maltez7, Alexandra Saltman8, Megan Himmel8, Ines Colmegna9, Lindsay Cho10, Emma Schmidt10, Claudie Berger11, Thomas Barnetche12, Lourdes Gonzalez Arreola13, Carrie Ye14, Shahin Jamal15 and Marie Hudson16, 1McGill University, Montreal, QC, Canada, 2Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 3Dalhousie University, Halifax, NS, Canada, 4University of Western Ontario, London, ON, Canada, 5University of Montreal, Brossard, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7The Ottawa Hospital, Ottawa, ON, Canada, 8University of Toronto, Toronto, ON, Canada, 9The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 10University of British Columbia, Vancouver, BC, Canada, 11RI-MUHC, Montreal, QC, Canada, 12Bordeaux University Hospital, Bordeaux, France, 13Arthritis Research Canada, Vancouver, BC, Canada, 14University of Alberta, Edmonton, AB, Canada, 15Vancouver Coastal Health, Vancouver, BC, Canada, 16McGill University, Montréal, QC, Canada

Meeting: ACR Convergence 2023

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), glucocorticoids, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. A drawback of ICI therapy is their off-target effects known as immune-related adverse events (irAEs), including inflammatory arthritis (ICI-IA). Glucocorticoids (GC) are among the first-line treatment for most irAEs, including ICI-IA. However, given the immunosuppressive properties of GC, there is concern that they may blunt the anti-tumor effects of ICI. There is a paucity of evidence on the safety of GC to treat ICI-IA. The aim of this study was to examine the impact of dose, timing of initiation and duration of GC on cancer outcomes in patients with ICI-IA. We hypothesized that highmaximal dose, early initiation and prolonged duration of GC exposure after onset of ICI-IA would be associated with worse outcomes.

Methods: The CanRIO retrospective cohort includes adult subjects with rheumatic irAEs after exposure to ICI, seen at one of 10 rheumatology clinics across Canada between Jan 2013 and Aug 2022, who have had standardized chart data extraction. In this sub-study, participants with de novo ICI-IA (without pre-existing IA), who were exposed to GC within 90 days after onset of IA, and in whom there was at least 3 months of follow up after onset of ICI-IA were analyzed. Data on maximal GC dose (max-GC dose), timing of GC initiation (time-GC) and duration of GC exposure (dur-GC) during the 90 days after the onset of ICI-IA were extracted. Median values for each were determined and used to dichotomize the exposure variables into above and below the median. Kaplan Meier analysis were used to evaluate the association between max-GC, time-GC and dur-GC with progression-free survival and overall survival.

Results: Data on 76 participants with de novo ICI-IA were available for analysis (Table 1). The median max-GC dose was 25 mg daily (interquartile range (IQR) 20-50 mg), median time-GC was 26.5 days (IQR 5-51 days) and median dur-GC was 59.5 days (IQR 30-82 days). Median follow up of the participants was 123.2 weeks. Max-GC dose, time-GC and dur-GC exposure had no association with progression-free and overall survival (Table 2 and Figure 1).

Conclusion: In this study of participants with de novo ICI-IA who were treated with GC, dose of GC, timing of initiation of GC and duration of GC exposure after onset of ICI-IA did not impact tumour outcomes. Although the confidence intervals were wide, our findings provide some reassurance about the safety of short-term GC for the management of ICI-IA. Further studies with larger sample size and longer term follow up are needed to corroborate our results, and additional studies comparing to ICI-IA patients unexposed to GC are needed to optimize management.

Supporting image 1

Table 1: Baseline characteristics of subjects exposed to glucocorticoid (GC) within 90 days after onset of ICI-IA (N=76).

Supporting image 2

Table 2: Disease progression and death in GC users by maximal GC dose, time to initiation of GC and duration of GC exposure after ICI-IA onset.

Supporting image 3

Figure 1: Progression-free and overall survival in weeks after onset of ICI-IA, stratified by the median of maximal dose, time to initiation and duration of GC within 90 days after ICI-IA onset.


Disclosures: V. Savarimuthu: None; A. Ladouceur: None; O. Terry: None; J. Roberts: None; J. Pope: AbbVie, 1, 2; T. Appleton: AbbVie/Abbott, 1, 2, 6, AstraZeneca, 1, 1, Celgene, 1, Eli Lilly, 1, Janssen, 1, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, Roche, 1, UCB, 1, 2, 6; S. Hoa: Boehringer-Ingelheim, 5; A. Fifi-Mah: Bristol-Myers Squibb(BMS), 5, Celltrion, 1, Frenesius-Kabi, 6, Novartis, 1, Otsuka, 1, Pfizer, 5, Sanofi, 1; N. Maltez: None; A. Saltman: None; M. Himmel: None; I. Colmegna: None; L. Cho: None; E. Schmidt: None; C. Berger: None; T. Barnetche: Eli Lilly, 2; L. Gonzalez Arreola: None; C. Ye: None; S. Jamal: AbbVie/Abbott, 1, 6, Eli Lilly, 1, GlaxoSmithKlein(GSK), 1, Merck/MSD, 1, 5, Pfizer, 1, 2, 6, UCB, 1, 2, 6; M. Hudson: AstraZeneca, 6, Boehringer-Ingelheim, 1, 5, 6, Bristol-Myers Squibb(BMS), 5, Merck, 6, UCB, 5.

To cite this abstract in AMA style:

Savarimuthu V, Ladouceur A, Terry O, Roberts J, Pope J, Appleton T, Hoa S, Fifi-Mah A, Maltez N, Saltman A, Himmel M, Colmegna I, Cho L, Schmidt E, Berger C, Barnetche T, Gonzalez Arreola L, Ye C, Jamal S, Hudson M. Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cancer-outcomes-in-cancer-patients-with-immune-checkpoint-inhibitor-induced-inflammatory-arthritis-treated-with-glucocorticoids-data-from-the-canrio-retrospective-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cancer-outcomes-in-cancer-patients-with-immune-checkpoint-inhibitor-induced-inflammatory-arthritis-treated-with-glucocorticoids-data-from-the-canrio-retrospective-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology